AG˹ٷ

STOCK TITAN

[Form 4] American Express Company Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) � Form 144 filing indicates an insider intends to sell 5,271 common shares on or about 02-Jul-2025 through Fidelity Brokerage on Nasdaq. The proposed sale represents �0.01&Բ;% of the company’s 52.5 million shares outstanding and carries an estimated market value of $9,396.

The filer—identified in the past-sales section as Nicholas Lynton—previously sold 6,057 shares in two transactions during April 2025, generating gross proceeds of $10,852. The shares to be sold were acquired via restricted-stock vesting on 01-Jul-2025 and are being disposed of for personal account purposes; no cash outlay was involved in the acquisition (classified as compensation).

Because the volume is immaterial relative to the float and no undisclosed adverse information is asserted, the filing is generally routine. Nonetheless, it signals continued insider selling within a three-month window, which investors may monitor for sentiment trends rather than fundamental impact.

Cardlytics, Inc. (CDLX) � Deposito Form 144 indica che un insider intende vendere 5.271 azioni ordinarie intorno al 02-lug-2025 tramite Fidelity Brokerage sul Nasdaq. La vendita proposta rappresenta circa lo 0,01% delle 52,5 milioni di azioni in circolazione della società, con un valore di mercato stimato di 9.396 $.

Il soggetto che effettua la vendita � identificato nella sezione delle vendite passate come Nicholas Lynton � ha già venduto in precedenza 6.057 azioni in due transazioni ad aprile 2025, generando proventi lordi per 10.852 $. Le azioni da vendere sono state acquisite tramite vesting di azioni vincolate il 01-lug-2025 e vengono cedute per scopi personali; l'acquisizione non ha comportato alcun esborso di denaro (classificata come compenso).

Poiché il volume è irrilevante rispetto al flottante e non sono segnalate informazioni negative non divulgate, il deposito è generalmente di routine. Tuttavia, segnala una continuazione delle vendite da parte degli insider in un arco temporale di tre mesi, che gli investitori potrebbero monitorare per cogliere tendenze di sentiment più che impatti fondamentali.

Cardlytics, Inc. (CDLX) � Presentación del Formulario 144 indica que un insider planea vender 5,271 acciones ordinarias alrededor del 02-jul-2025 a través de Fidelity Brokerage en Nasdaq. La venta propuesta representa aproximadamente el 0,01% de las 52,5 millones de acciones en circulación de la compañía y tiene un valor de mercado estimado de $9,396.

El declarante � identificado en la sección de ventas pasadas como Nicholas Lynton � vendió previamente 6,057 acciones en dos transacciones durante abril de 2025, generando ingresos brutos de $10,852. Las acciones a vender fueron adquiridas mediante vesting de acciones restringidas el 01-jul-2025 y se están disponiendo para fines personales; no se realizó ningún desembolso de efectivo en la adquisición (clasificada como compensación).

Dado que el volumen es insignificante en relación con el flotante y no se afirma información adversa no divulgada, la presentación es generalmente rutinaria. Sin embargo, señala una continuación de ventas por parte de insiders en un período de tres meses, que los inversores podrían monitorear para detectar tendencias de sentimiento más que impactos fundamentales.

Cardlytics, Inc. (CDLX) � Form 144 제출� 내부자가 2025� 7� 2일경 Fidelity Brokerage� 통해 5,271� 보통�� 매도� 의사가 있음� 나타냅니�. 제안� 매도� 회사� 5,250� � 발행 주식� � 0.01%� 해당하며, 추정 시가 총액은 $9,396입니�.

신고인—과� 매도 내역� Nicholas Lynton으로 명시된—는 2025� 4� � 건의 거래에서 6,057�� 매도하여 � $10,852� 수익� 올린 � 있습니다. 매도 예정 주식은 2025� 7� 1� 제한 주식 베스�� 통해 취득되었으며, 개인 계좌 목적으로 처분됩니�; 취득 � 현금 지출은 없었으며(보상으로 분류�)니다.

거래량이 유통 주식 수에 비해 미미하고 공개되지 않은 부정적 정보가 없으므�, 이번 제출은 일반적으� 일상적인 절차입니�. 그럼에도 불구하고 이는 3개월 � 지속적� 내부� 매도� 의미하며, 투자자들은 펀더멘� 영향보다� 시장 심리 동향� 모니터링� � 있습니다.

Cardlytics, Inc. (CDLX) � Dépôt du Formulaire 144 indique qu’un initié prévoit de vendre 5 271 actions ordinaires aux alentours du 02-juil-2025 via Fidelity Brokerage sur le Nasdaq. La vente proposée représente environ 0,01 % des 52,5 millions d’actions en circulation de la société, avec une valeur marchande estimée à 9 396 $.

Le déclarant � identifié dans la section des ventes passées comme Nicholas Lynton � a précédemment vendu 6 057 actions en deux transactions en avril 2025, générant un produit brut de 10 852 $. Les actions à vendre ont été acquises via un vesting d’actions restreintes le 01-juil-2025 et sont cédées à des fins personnelles ; aucune dépense en espèces n’a été engagée lors de l’acquisition (classifiée comme rémunération).

Étant donné que le volume est négligeable par rapport au flottant et qu’aucune information défavorable non divulguée n’est signalée, le dépôt est généralement de routine. Néanmoins, il signale une poursuite des ventes par des initiés sur une période de trois mois, que les investisseurs peuvent surveiller pour détecter des tendances de sentiment plutôt que des impacts fondamentaux.

Cardlytics, Inc. (CDLX) � Form 144 Einreichung zeigt an, dass ein Insider beabsichtigt, am oder um den 02.07.2025 etwa 5.271 Stammaktien über Fidelity Brokerage an der Nasdaq zu verkaufen. Der vorgeschlagene Verkauf entspricht etwa 0,01 % der 52,5 Millionen ausstehenden Aktien des Unternehmens und hat einen geschätzten Marktwert von 9.396 $.

Der Einreicher � in der Sektion der vergangenen Verkäufe als Nicholas Lynton identifiziert � verkaufte zuvor im April 2025 in zwei Transaktionen 6.057 Aktien und erzielte Bruttoerlöse von 10.852 $. Die zu verkaufenden Aktien wurden durch Restricted-Stock-Vesting am 01.07.2025 erworben und werden aus persönlichen Gründen veräußert; beim Erwerb fiel kein Bargeldaufwand an (als Vergütung klassifiziert).

Da das Volumen im Verhältnis zum Streubesitz unerheblich ist und keine nicht offengelegten negativen Informationen vorliegen, ist die Einreichung im Allgemeinen routinemäßig. Dennoch signalisiert sie fortgesetzten Insiderverkauf innerhalb eines Dreimonatszeitraums, den Investoren eher zur Beobachtung von Stimmungsentwicklungen als für fundamentale Auswirkungen nutzen könnten.

Positive
  • None.
Negative
  • Continued insider selling within a three-month span may signal weak insider confidence, albeit at immaterial volume.

Insights

TL;DR � Minor Form 144: 5,271-share insider sale, negligible to float, modest negative sentiment only.

The notice covers an insider’s intent to sell roughly $9.4k worth of stock—less than 0.02 days of CDLX’s typical trading volume and 0.01 % of outstanding shares. The shares stem from a recent RSU vest. Two prior April sales total $10.9k, suggesting a pattern of small disposition linked to compensation events rather than a strategic exit. No operational or financial data accompany the filing; therefore, valuation or earnings outlook remain unaffected. Impact on share price should be de minimis, but persistent micro-scale insider selling can incrementally weigh on investor sentiment.

TL;DR � Routine Rule 144 filing; compliance positive, but insider sales may raise perception issues.

Timely disclosure under Rule 144 demonstrates adherence to SEC resale regulations, mitigating regulatory risk. The transaction volume is well below Rule 144 volume limits, and the seller attests to possessing no undisclosed material information, supporting governance standards. While compliance is a positive, recurring insider sales—three within one quarter—could be interpreted as lukewarm confidence, especially if unaccompanied by offsetting purchases.

Cardlytics, Inc. (CDLX) � Deposito Form 144 indica che un insider intende vendere 5.271 azioni ordinarie intorno al 02-lug-2025 tramite Fidelity Brokerage sul Nasdaq. La vendita proposta rappresenta circa lo 0,01% delle 52,5 milioni di azioni in circolazione della società, con un valore di mercato stimato di 9.396 $.

Il soggetto che effettua la vendita � identificato nella sezione delle vendite passate come Nicholas Lynton � ha già venduto in precedenza 6.057 azioni in due transazioni ad aprile 2025, generando proventi lordi per 10.852 $. Le azioni da vendere sono state acquisite tramite vesting di azioni vincolate il 01-lug-2025 e vengono cedute per scopi personali; l'acquisizione non ha comportato alcun esborso di denaro (classificata come compenso).

Poiché il volume è irrilevante rispetto al flottante e non sono segnalate informazioni negative non divulgate, il deposito è generalmente di routine. Tuttavia, segnala una continuazione delle vendite da parte degli insider in un arco temporale di tre mesi, che gli investitori potrebbero monitorare per cogliere tendenze di sentiment più che impatti fondamentali.

Cardlytics, Inc. (CDLX) � Presentación del Formulario 144 indica que un insider planea vender 5,271 acciones ordinarias alrededor del 02-jul-2025 a través de Fidelity Brokerage en Nasdaq. La venta propuesta representa aproximadamente el 0,01% de las 52,5 millones de acciones en circulación de la compañía y tiene un valor de mercado estimado de $9,396.

El declarante � identificado en la sección de ventas pasadas como Nicholas Lynton � vendió previamente 6,057 acciones en dos transacciones durante abril de 2025, generando ingresos brutos de $10,852. Las acciones a vender fueron adquiridas mediante vesting de acciones restringidas el 01-jul-2025 y se están disponiendo para fines personales; no se realizó ningún desembolso de efectivo en la adquisición (clasificada como compensación).

Dado que el volumen es insignificante en relación con el flotante y no se afirma información adversa no divulgada, la presentación es generalmente rutinaria. Sin embargo, señala una continuación de ventas por parte de insiders en un período de tres meses, que los inversores podrían monitorear para detectar tendencias de sentimiento más que impactos fundamentales.

Cardlytics, Inc. (CDLX) � Form 144 제출� 내부자가 2025� 7� 2일경 Fidelity Brokerage� 통해 5,271� 보통�� 매도� 의사가 있음� 나타냅니�. 제안� 매도� 회사� 5,250� � 발행 주식� � 0.01%� 해당하며, 추정 시가 총액은 $9,396입니�.

신고인—과� 매도 내역� Nicholas Lynton으로 명시된—는 2025� 4� � 건의 거래에서 6,057�� 매도하여 � $10,852� 수익� 올린 � 있습니다. 매도 예정 주식은 2025� 7� 1� 제한 주식 베스�� 통해 취득되었으며, 개인 계좌 목적으로 처분됩니�; 취득 � 현금 지출은 없었으며(보상으로 분류�)니다.

거래량이 유통 주식 수에 비해 미미하고 공개되지 않은 부정적 정보가 없으므�, 이번 제출은 일반적으� 일상적인 절차입니�. 그럼에도 불구하고 이는 3개월 � 지속적� 내부� 매도� 의미하며, 투자자들은 펀더멘� 영향보다� 시장 심리 동향� 모니터링� � 있습니다.

Cardlytics, Inc. (CDLX) � Dépôt du Formulaire 144 indique qu’un initié prévoit de vendre 5 271 actions ordinaires aux alentours du 02-juil-2025 via Fidelity Brokerage sur le Nasdaq. La vente proposée représente environ 0,01 % des 52,5 millions d’actions en circulation de la société, avec une valeur marchande estimée à 9 396 $.

Le déclarant � identifié dans la section des ventes passées comme Nicholas Lynton � a précédemment vendu 6 057 actions en deux transactions en avril 2025, générant un produit brut de 10 852 $. Les actions à vendre ont été acquises via un vesting d’actions restreintes le 01-juil-2025 et sont cédées à des fins personnelles ; aucune dépense en espèces n’a été engagée lors de l’acquisition (classifiée comme rémunération).

Étant donné que le volume est négligeable par rapport au flottant et qu’aucune information défavorable non divulguée n’est signalée, le dépôt est généralement de routine. Néanmoins, il signale une poursuite des ventes par des initiés sur une période de trois mois, que les investisseurs peuvent surveiller pour détecter des tendances de sentiment plutôt que des impacts fondamentaux.

Cardlytics, Inc. (CDLX) � Form 144 Einreichung zeigt an, dass ein Insider beabsichtigt, am oder um den 02.07.2025 etwa 5.271 Stammaktien über Fidelity Brokerage an der Nasdaq zu verkaufen. Der vorgeschlagene Verkauf entspricht etwa 0,01 % der 52,5 Millionen ausstehenden Aktien des Unternehmens und hat einen geschätzten Marktwert von 9.396 $.

Der Einreicher � in der Sektion der vergangenen Verkäufe als Nicholas Lynton identifiziert � verkaufte zuvor im April 2025 in zwei Transaktionen 6.057 Aktien und erzielte Bruttoerlöse von 10.852 $. Die zu verkaufenden Aktien wurden durch Restricted-Stock-Vesting am 01.07.2025 erworben und werden aus persönlichen Gründen veräußert; beim Erwerb fiel kein Bargeldaufwand an (als Vergütung klassifiziert).

Da das Volumen im Verhältnis zum Streubesitz unerheblich ist und keine nicht offengelegten negativen Informationen vorliegen, ist die Einreichung im Allgemeinen routinemäßig. Dennoch signalisiert sie fortgesetzten Insiderverkauf innerhalb eines Dreimonatszeitraums, den Investoren eher zur Beobachtung von Stimmungsentwicklungen als für fundamentale Auswirkungen nutzen könnten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
VASELLA DANIEL

(Last) (First) (Middle)
C/O AMERICAN EXPRESS COMPANY
200 VESEY STREET

(Street)
NEW YORK NY 10285-5001

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMERICAN EXPRESS CO [ AXP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Equivalent Units (1) 06/30/2025 A(2) 115.837 (3) (3) Common Stock 115.837 $302.15 45,430.438(4) D
Explanation of Responses:
1. Each Share Equivalent Unit reflects the value of one common share.
2. The reported Share Equivalent Units were acquired pursuant to the Directors' Deferred Compensation Plan and will be settled in cash following termination of service as a Director.
3. The Share Equivalent Units are convertible immediately upon termination of service as a Director and have no expiration date.
4. Includes Share Equivalent Units acquired pursuant to a dividend reinvestment feature of the Directors' Deferred Compensation Plan and/or the 2003 Share Equivalent Unit Plan for Directors.
/s/ John Nowak, attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CDLX shares are being sold under this Form 144?

5,271 common shares are slated for sale.

What is the estimated market value of the planned CDLX share sale?

The proposed sale is valued at approximately $9,396.

When is the insider planning to sell the CDLX shares?

The approximate sale date disclosed is 02-Jul-2025.

How many CDLX shares were sold by the insider in the past three months?

Two prior transactions in April 2025 disposed of 6,057 shares in total.

What percentage of Cardlytics� outstanding shares does the 5,271-share sale represent?

It represents about 0.01 % of the 52.5 million shares outstanding.

How were the shares being sold originally acquired?

They were received through restricted-stock vesting on 01-Jul-2025 as part of compensation.
American Express Co

NYSE:AXP

AXP Rankings

AXP Latest News

AXP Latest SEC Filings

AXP Stock Data

218.18B
547.87M
21.75%
65.6%
1.18%
Credit Services
Finance Services
United States
NEW YORK